SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here
A $1,000 investment in SLS at the end of 2025 was worth about $5,080 at Tuesday’s close. Among biotech stocks worth at least $500 million, only Moderna and Adlai Nortye ranked ahead of Sellas. STAT columnist Adam Feuerstein acknowledged he had been wrong …